HanchorBio Founder Dr. Scott Liu Invited to Moderate at BIOCHINA 2026

BIOCHINA 2026 (11th BIOCHINA Annual Conference & Expo) will be held from March 12–14, 2026 in Suzhou, China. Dr. Scott Liu, Founder, Chairman and Chief Executive Officer of HanchorBio Inc., has been invited to attend the conference and will serve as a roundtable moderator at the Antibody Drug Innovation & Development Forum, as well as participate as a featured interview and discussion speaker.

Event Information

• Event Name: BIOCHINA 2026 (11th BIOCHINA Annual Conference & Expo)

• Date: March 12–14, 2026

• Location: Suzhou, China

• Official Link:
  https://event.morebio.cn/schedule-pc/125cc224-2393-45d3-987f-7f28004966c9/special/1520

Forum & Interview Details

• Forum: Antibody Drug Innovation & Development Forum

  • Featured Interview & Discussion Speaker

• Interview Topic:
  “Focused Strategies in Specialized Segments — Insights from BD Transactions on the Positioning and Collaborative Strategy of Bispecific and Multispecific Antibody Innovation”

Dr. Scott Liu will share perspectives drawn from his extensive experience in global licensing, innovative antibody development, and corporate strategy, offering insights into how BD transactions shape competitive positioning and collaborative ecosystems in the dual/multi-antibody landscape.

About BIOCHINA

Founded in 2016, BIOCHINA is dedicated to building a global platform for collaboration and exchange within the biopharmaceutical industry. It has grown into one of the most influential life sciences industry events in the Asia-Pacific region.

Expected scale of BIOCHINA 2026:

• 30,000+ attendees

• 40+ countries and regions represented

• 850+ speakers

• 250+ sub-forums

• 3,000+ partnering meetings

• 400+ exhibitors

The conference will bring together leaders from biotechnology, pharmaceutical companies, research institutions, and the investment community to explore advances in biologics innovation, clinical development, and international collaboration.

Speaker Profile

Dr. Scott Liu

Founder, Chairman & Chief Executive Officer of HanchorBio Inc.

Dr. Scott Liu is the Founder, Chairman and CEO of HanchorBio, a clinical-stage global biotechnology company focused on the development of innovative immuno-oncology therapeutics. The Company leverages its proprietary Fc-Based Designer Biologics (FBDB) platform to engineer multifunctional fusion biologics targeting diverse mechanisms of action, aiming to reactivate the immune system to treat multiple cancers.

HanchorBio’s lead candidate, HCB101, developed using the FBDB platform, has demonstrated efficacy and safety across cell-based, murine, and non-human primate studies. It is currently undergoing global Phase 1 clinical trials (including the U.S., Mainland China, and Taiwan), with encouraging preliminary observations in patients. The program has progressed into Phase 1b/2 clinical studies in 2025, targeting gastric cancer, triple-negative breast cancer, and head and neck cancers.

The Company’s second program, HCB301, a tri-functional fusion biologic, is also in Phase 1 clinical trials in the U.S. and Mainland China, with early dose cohorts demonstrating favorable safety. Additional oncology and autoimmune biologics are advancing through preclinical and clinical development.

Prior to founding HanchorBio, Dr. Liu was a global partner of Fosun International and co-founder, President, and CEO of Shanghai Henlius Biotech (HKEX: 2696), a commercial-stage global biopharmaceutical company. Under his leadership, Henlius advanced over 30 product development programs—including biosimilars, novel monoclonal antibodies, and bispecific antibodies—and successfully launched multiple antibody products in China and Europe.

Dr. Liu brings more than 30 years of experience in corporate strategy, portfolio management, quality operations, GMP manufacturing, and regulatory affairs. He previously held senior positions at United Biomedical, Bristol-Myers Squibb, and Amgen. He earned his Ph.D. in Biology from Purdue University and completed postdoctoral research at Stanford University. He also served as Associate Professor at National Sun Yat-sen University in Taiwan.

We Look Forward to Connecting in Suzhou

HanchorBio warmly invites industry partners and colleagues to join BIOCHINA 2026. We look forward to engaging with global experts, exchanging forward-looking insights, and exploring new collaboration opportunities in Suzhou.